Diagnostic Performance of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Pre-operative Lymph Node Assessment in Intermediate and High-risk Nonmetastasic Prostate Cancer
Key facts
- Where
- Brest, FranciaországSee the site
- Phase
- 2. fázis
Where in Franciaország
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Regional Et Universitaire De Brest
- Trial code
- EU 2024-516319-25-00
- Record updated
- 2025. április 30.
- Original description
To determine the diagnostic performance of Positron Emission Tomography with Prostate Specific Membrane Antigen Ligands (PET-PSMA) for the detection of lymph node metastases in intermediate or high-risk prostatic neoplasia for which radical treatment by prostatectomy is selected by the multidisciplinary consultation meetingRead full original descriptionShow less
To determine the diagnostic performance of Positron Emission Tomography with Prostate Specific Membrane Antigen Ligands (PET-PSMA) for the detection of lymph node metastases in intermediate or high-risk prostatic neoplasia for which radical treatment by prostatectomy is selected by the multidisciplinary consultation meeting
Inclusion: Patients over 18 years of age; Histologically confirmed prostatic neoplasia; Intermediate-risk neoplasia (PSA between 10 and 20 ng/mL and/or TR showing T2b and/or ISUP 2 or 3, AND with risk of lymph node extension > 5% according to the Briganti nomogram) or high-risk neoplasia (PSA ≥ 20 ng/mL and/or TR ≥ T2c and/or ISUP 4 or 5) according to the d'Amico classification; Radical treatment by total prostatectomy selected by the multidisciplinary consultation meeting; Patient affiliated to or benefiting from a health insurance scheme.
Exclusion: Curative treatment other than surgery selected; Refusal or inability to take part in the study; Prostatic neoplasia with low risk of extension according to the Amico classification, or intermediate risk but with a risk of lymph node extension <5% according to the Briganti nomogram; Life expectancy < 12 months; Karnofsky score < 70 or ECOG score > 2; Patient under guardianship or trusteeship.